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Mass drug administration (MDA) is the main strategy towards lymphatic filariasis (LF) elimination. Progress is monitored by assessing microfilaraemia (Mf) or circulating filarial antigenaemia (CFA) prevalence, the latter being more practical for field surveys. The current
criterion for stopping MDA requires <2% CFA prevalence in 6- to 7-year olds, but this criterion is not evidence-based. We used mathematical modelling to investigate the validity of
different thresholds regarding testing method and age group for African MDA programmes
using ivermectin plus albendazole.

Methodolgy/Principal findings
We verified that our model captures observed patterns in Mf and CFA prevalence during
annual MDA, assuming that CFA tests are positive if at least one adult worm is present. We
then assessed how well elimination can be predicted from CFA prevalence in 6-7-year-old
children or from Mf or CFA prevalence in the 5+ or 15+ population, and determined safe
(>95% positive predictive value) thresholds for stopping MDA. The model captured trends in
Mf and CFA prevalences reasonably well. Elimination cannot be predicted with sufficient
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Stopping decisions in lymphatic filariasis elimination programmes

certainty from CFA prevalence in 6-7-year olds. Resurgence may still occur if all children are
antigen-negative, irrespective of the number tested. Mf-based criteria also show unfavourable results (PPV <95% or unpractically low threshold). CFA prevalences in the 5+ or 15+
population are the best predictors, and post-MDA threshold values for stopping MDA can be
as high as 10% for 15+. These thresholds are robust for various alternative assumptions
regarding baseline endemicity, biological parameters and sampling strategies.

Conclusions/Significance
For African areas with moderate to high pre-treatment Mf prevalence that have had 6 or
more rounds of annual ivermectin/albendazole MDA with adequate coverage, we recommend to adopt a CFA threshold prevalence of 10% in adults (15+) for stopping MDA. This
could be combined with Mf testing of CFA positives to ensure absence of a significant Mf
reservoir for transmission.

Author summary
Mass drug administration (MDA) of antifilarial drugs is the main strategy towards the
elimination of lymphatic filariasis (LF), but defining when MDA can safely be stopped is
challenging. Current stopping guidelines require that the prevalence of microfilaraemia
(Mf) in the population falls below 1% or the prevalence of circulating filarial antigenaemia
(CFA) in 6-and-7-year-old children falls below 2%. The evidence base underlying this
threshold is limited. The accuracy of this threshold is hard to assess in field studies due to
the long timespan between stopping MDA and the occurrence of either elimination or
resurgence. We used mathematical modelling to assess how well elimination can be predicted at community-level from the Mf or CFA prevalence observed 1-year after the last
MDA round and we determined safe stopping thresholds (>95% certainty that elimination is achieved). We found that the currently used CFA prevalence in 6–7 year-old children is a poor indicator for stopping decisions in LF elimination programmes
implementing MDA with ivermectin plus albendazole, and that CFA prevalence among
people aged 5 or 15 years and older is a much more reliable and practical indicator of
elimination outcomes. Lymphatic filariasis elimination programmes should reconsider
guidelines for stopping MDA.

Introduction
Lymphatic filariasis (LF) is a mosquito-transmitted parasitic worm infection that prevails in
tropical and subtropical regions across the world and is an important preventable cause of
morbidity and disability [1]. Most LF is caused by the filarial nematode Wuchereria bancrofti.
The long-lived adult worms reside in the human lymph system and are the main cause of morbidity (lymphoedema and hydrocele). Fertilized female worms release large numbers of microfilariae (worm’s offspring) into the bloodstream, where they can be picked up by mosquitoes
to be passed on to other humans. Annual mass drug administration (MDA) is the mainstay of
control, sometimes complemented by vector control measures such as the use of insecticidetreated bed nets.
The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was initiated in 2000. It
aims to eliminate LF as a public health problem by interrupting transmission through MDA of
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anti-filarial drugs (albendazole with ivermectin and/or diethylcarbamazine, with the threedrug combination restricted to specific settings warranting acceleration[2]) and by alleviating
the suffering of people with clinical manifestations through morbidity management and disability prevention [3,4]. The rapid scale-up of MDA has led to a massive decline in the prevalence of LF infection. By 2020, 17 previously endemic countries no longer require MDA after
reaching prevalence targets below which transmission is thought to be unsustainable [1]. Eight
more have stopped all MDA and are now under surveillance to confirm elimination as a public
health problem based on WHO criteria; 47 countries still require MDA in some or all of their
endemic areas [5].
Progress towards elimination of W. bancrofti is monitored by examining trends in microfilaraemia (Mf) or circulating filarial antigenaemia (CFA) prevalence [6]. Based on experiences
from China [7], a Mf prevalence below 1% is thought to lead to elimination where infection is
transmitted by Anopheles or Culex mosquito species [6]. A lower threshold target is recommended where more efficient Aedes species transmit the parasites [6]. However, Mf prevalence
surveys require microscopic examination of blood samples, and are extra cumbersome in
areas such as Africa where night blood samples are needed because of nocturnal Mf periodicity. In contrast, CFA can be detected in day or night blood with a rapid point of care test that
does not require microscopy [8,9]. The World Health Organization (WHO) therefore defined
its stop-MDA recommendations based on CFA prevalence, which is to be assessed in 67-year-old children according to a specifically designed transmission assessment survey (TAS)
[6]. MDA can be stopped if CFA prevalence is <2% where Anopheles or Culex are the main
vectors and <1% where Aedes is the main vector [6]. Children are taken as sentinel group, as
they should be free of LF infection if transmission is successfully interrupted. TAS is to be
repeated two more times with intervals of two to three years between surveys, to validate elimination as a public health problem.
The TAS design was found to be practical, but whether this is sufficient to eliminate transmission and sustain the results in the long run remains uncertain [10]. There is concern that
CFA prevalence in children is not a sensitive enough indicator for detecting residual transmission [11]. Children are not always exposed to the same number of infective mosquitoes as
adults and may be CFA negative while transmission is ongoing in the adult population. Also,
there is concern that the currently-used threshold is too stringent when the Alere Filariasis
Test Strip (FTS) is used to detect CFA, because it is more sensitive than the previously used
immunochromatographic card test (ICT); many FTS-positives are Mf negative and are therefore unlikely to contribute to transmission [12,13].
Mathematical models are useful tools to theoretically assess the validity of MDA stopping
thresholds [14,15]. Modelling showed that the risk of LF resurgence is low in African settings
where Mf prevalence in the 5+ population was reduced to <1% after five rounds of MDA with
ivermectin plus albendazole [15]. Here, we use the established LYMFASIM model to assess the
predictive value of Mf and CFA prevalence thresholds for the eventual occurrence of resurgence or elimination of LF, in relation to the sampled age group, for African LF elimination
programmes implementing annual MDA with ivermectin plus albendazole. Before doing so,
we verify that the model adequately captures the observed association between communitylevel Mf and CFA prevalence, before and during annual MDA.

Methods
The LYMFASIM model
LYMFASIM is an individual-based model, simulating LF transmission in a population (village
or town) of hypothetical individuals [16,17]. The model tracks infection intensity (number of
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male and female adult worms; Mf density) for each individual, accounting for inter-individual
variation in exposure to infection and participation in interventions. It captures the key processes involved in parasite biology, transmission and interventions. See section 1 in S1 Supplement for more information. LYMFASIM accounts for measurement variation in counting Mf,
allowing for the occurrence of false-negative Mf counts for individuals with low worm burdens. For the current analysis, we assumed that all individuals with �1 mature male or female
worm are CFA-positive, and that people turn CFA-negative within one month after a person’s
last worm has died.

Validation of model-predicted CFA prevalences
We validated model-predicted CFA prevalences using individual-level data from annuallytreated communities from community intervention trials in Côte d’Ivoire (primary results will
be published elsewhere) and Liberia[18] evaluating the effectiveness of annual versus biannual
MDA on LF infection. Only for validating the model-predicted association between Mf and
CFA prevalences at baseline (2013 for Côte d’Ivoire, 2014 for Liberia) we also used baseline
data from biannually-treated communities.
We simulated the local history of control at community level, accounting for the timing of
MDA rounds and surveys, and for the local bed net coverage since 2006. To obtain simulation
runs across the spectrum of observed baseline endemicity levels, we performed a large number
of runs per scenario, varying model parameters relating to setting-specific transmission conditions: the monthly biting rate, the degree of interindividual variation in exposure to mosquito
bites, and external force-of-infection (i.e. the rate at which infection are acquired from outside
the simulated population due to human or vector mobility). The external force-of-infection
was set to zero in half of the simulation runs, to mimic communities where transmission is
independent of imported infections. In the other runs, it was set to a low value, varying
between runs but constant over time to mimic communities where low endemicity is stabilized
by incoming infection from surrounding areas.
We then checked whether the model-predicted association between mf and CFA prevalences matched to village-level data at baseline and after the first, second and third annual
treatment. We further assessed whether the model adequately captures time trends in infection. Lastly, we compared model-predicted and observed age-patterns in infection for all measurements moment, aggregating data from different communities by country. A more detailed
description of the data and validation methods is provided in section 2 in S1 Supplement.

Predictive values of Mf and CFA prevalence for elimination and resurgence
We assessed how well the eventual occurrence of elimination of transmission can be predicted
based on the Mf or CFA prevalence one year after the last treatment round. We simulated four
MDA scenarios with either six or eight annual rounds of MDA with ivermectin plus albendazole, and either 60% or 80% treatment coverage of the total population (with treatment
restricted to individuals aged 5 years or older). Bed net use was not considered in these simulations, as we were interested in the dynamics of resurgence and elimination in the absence of
bed nets.
This analysis was done for settings with an average population size of about 1000 individuals and a moderate to high baseline Mf prevalence (i.e. between 20% and 40%). We only considered settings without importation of infection from surrounding areas (external force of
infection = 0), so that elimination outcomes were not influenced by the presence or absence of
importation from surrounding areas. Between runs we varied the monthly biting rate and the
shape of the gamma distribution describing variation in exposure between individuals.
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Parameters were sampled from the parameter space presented in Fig A in S1 Supplement (left
panel) and were accepted when the resulting pre-control Mf prevalence fell into one of the 1%width bins between 20% and 40%; the model was run until we had 100 parameter combinations per bin, resulting in 2000 runs per scenario.
For each run, we recorded predicted time trends in Mf and CFA prevalence in the population aged 5 or 15 years and above, as well as the CFA prevalence among 6-7-year-old children,
from a year before the first treatment until 50 years after the last treatment round. Elimination
was defined as zero Mf prevalence in the 5+ population 50 years after the last treatment round.
To assess to which extent the eventual occurrence of elimination can be predicted based on Mf
and CFA prevalence surveys done 1 year after the last treatment, we calculate receiver operating characteristic (ROC) curves for a range of prevalence thresholds, assuming that all individuals per age group are examined. For the calculation of PPV and NPV values, we assumed that
a random binomial sample of 200 individuals in the respective age group was surveyed (sampled with replacement); as the number of 6-7-year olds is much lower than this, this implies
that nearly all individuals in this age group are included in the survey. This sampling was
repeated 100 times to smooth the resulting predictions. Stop-MDA thresholds were estimated
at a PPV of 95%. A sample size of 200 was chosen, assuming that this would be a practically
feasible number, but alternative values were also used in a sensitivity analysis.
Lastly, we assessed how assumptions regarding the rate of Mf production per worm (which
influences the association between Mf density and the underlying number of worms) affect the
predicted elimination thresholds. The Mf productivity rate was doubled or halved from 0�58
(estimated previously by fitting model to data)[17] to 1�16 or 0�29 Mf/μL blood per female
worm per month); to counter the impact on transmission intensity, we simultaneously halved
or doubled the mosquito biting rates (see Fig B in S1 Supplement).

PRIME-NTD principles
In S1 Supplement section 3, we describe our adherence to the five principles of the NTD
Modelling Consortium on good practice for policy-relevant modelling [19].

Results
Comparison of model-predicted and observed Mf-CFA prevalence
associations
Fig 1 shows that model-predicted Mf-CFA prevalence combinations before the introduction
of MDA matched well to observed data. The FTS-based observed CFA prevalences from Côte
d’Ivoire were relatively high, considering the corresponding Mf prevalences, but could be
matched by the model by including importation of infection from surrounding areas. The
ICT-based observed CFA prevalences for Liberia were often relatively low for given Mf prevalences and could often be captured without assuming infection importation.
Fig 2 shows that the model also adequately captured the association between communitylevel Mf and CFA prevalence in Côte d’Ivoire during MDA (11 months after the first, second
and third treatment round). However, the predicted Mf and CFA prevalence levels per village
for the follow-up moment did not always match the observations. Deviations can result from
sampling variation in the observed data (sometimes leading to erratic patterns in the data that
are not mimicked by the model) or from a mismatch between assumed and actual coverage of
MDA (true coverage is unknown and can vary over time and between communities). Fig C in
S1 Supplement presents similar results for Liberia, which are somewhat more difficult to interpret due to a switch in CFA diagnostic from ICT at baseline to FTS in later surveys, with the
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Fig 1. Comparison of the model-predicted and observed pre-treatment association between microfilaraemia (Mf) and circulating filarial
antigenaemia (CFA) prevalence at community-level. Observed data are from villages in the annual and biannual treatment arms in Côte
d’Ivoire (triangles) and Liberia (squares), with CFA prevalences assessed using either the filarial test strip (FTS, black) or the
immunochromatographic card test (ICT, white). FTS- and ICT-based observations made in the same community are connected via black dotted
lines. Model predictions (dots) are shown for settings without (dark blue) and with (light blue) an external force of infection.
https://doi.org/10.1371/journal.pntd.0010953.g001

latter resulting in somewhat higher CFA prevalences (indicated by observations from communities were both tests were used in parallel). At baseline, the observed prevalences from Liberia
were usually located within the band of predicted values, whereas they were close to the upper
edge of the model predictions band or even above it at the three follow-up moments. This was
most extreme after the third treatment round, when Mf-prevalence was zero in all communities but CFA prevalence up to 13% were observed. Various factors could contribute to the deviation between model predictions and observations, including uncertainty about MDA
coverage and treatment effects on adult worms. A lag in antigen clearance after worm killing
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Fig 2. Observed and simulated prevalence of microfilaraemia (Mf) and circulating filarial antigenaemia (CFA,
measured by filarial test strip) for Côte d’Ivoire, at baseline (2014, before the first treatment round) and in 2015,
2016, and 2017 (i.e. 11 months after the first, second and third annual MDA rounds). Observations are shown as
coloured markers with 95% confidence intervals. Model predictions are shown as small dots. Simulation results from
runs matched to specific villages at baseline are shown in the colour of that village, and all other runs are shown in
grey. A run was considered a match if the predicted Mf-CFA prevalence combination at baseline fell within the ellipse
drawn around the observed MF-CFA prevalence combination based on the 95% confidence intervals. For both the
model and the observed data, crude prevalence estimates are presented in the figures (i.e. not age-standardized). The
MDA coverage was assumed to be 65% of the total population per round in the simulation runs. See Table B in S1
Supplement for details about the simulated scenario and see Fig C in S1 Supplement for a similar figure for Liberia.
https://doi.org/10.1371/journal.pntd.0010953.g002

could theoretically also explain some of these results. However, due to the long time-interval
between treatment and the follow-up surveys, this is not the most likely explanation. Also, if
this plays a role, we would expect it to be visible in both countries and not only in Liberia. The
observed reductions in Mf and CFA prevalence were larger than predicted by the model, for
most villages, again suggesting a mismatch between assumed and actual coverage of MDA.
Still, for both Liberia and Côte d’Ivoire the observed Mf and CFA prevalence combinations
were all on or near the model-predicted associations.
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Figs D and E in S1 Supplement show that the model also captured the age-patterns in Mf
and CFA prevalence, including the considerably lower prevalence levels in children compared
to adults.

Predictive performance of MF- and CFA-based stop-MDA thresholds
Model-predicted trends in Mf and CFA prevalence during and after MDA (six or eight
rounds, 60% of 80% coverage) are shown in Figs F and G in S1 Supplement for settings with
baseline Mf prevalence between 20%-30% and 30%-40% in the population aged 5 years and
above. Longer duration of MDA and higher coverage resulted in lower Mf and CFA prevalence one year after the last treatment and higher probability of elimination. The ROC
curves in Fig 3 show how well the eventual occurrence of elimination could be predicted
from Mf and CFA prevalence one year post-MDA, for different age groups (assuming that
all individuals per age group are included in the survey) and for a range of different threshold values. Adopting a higher threshold value results in a higher sensitivity (i.e. a higher proportion of runs ending in elimination correctly classified as such, based on a prevalence
below the chosen threshold), but also a lower specificity (i.e. a lower proportion of runs ending in resurgence correctly classified as such, based on a prevalence above the chosen threshold). This lower specificity means a higher probability of falsely declaring elimination and
prematurely stopping MDA, the most important adverse outcome. In the scenario with six
treatment rounds with 60% coverage, the Mf prevalence in the 5+ or 15+ population seemed
to be a slightly better indicator of elimination than CFA prevalence in any of the age groups
considered. However, the overall probability of elimination was still low in this scenario
(43% of all runs). The predictive value of CFA prevalence in the 5+ or 15+ population
increased with longer MDA and higher coverage, and hence higher elimination probability.
The CFA prevalence in the 5+ and 15+ population clearly were the best predictors in the scenario with eight treatment rounds and 80% coverage and the CFA prevalence among 67-year olds was the worst predictor, independently of the threshold considered. In this scenario, about 87% of runs resulted in elimination. These patterns remained when the results
were further stratified by endemicity, based on baseline Mf prevalence in the 5+ population
(Fig H in S1 Supplement).
Fig 4 shows per indicator how the PPV (probability of achieving elimination within 50
years after the last round of MDA if the 1-year post MDA prevalence in a sample of 200 individuals per age group was below a given threshold) depended on the chosen threshold. The
PPV never reached 100% for CFA prevalence among 6-7-year olds and Mf prevalence in samples of the 5+ or 15+ population. This means that there was still a risk of resurgence, even
when the simulated CFA or Mf prevalence was zero. A PPV value of 100% could only be
achieved with the stop criterion based on CFA prevalence in the 5+ or 15+ population. The
threshold prevalence associated with a 95% PPV was about 0�5% for the Mf prevalence in the
15+ population, if reached at all. The thresholds based on CFA prevalence in the 5+ and 15
+ population were much higher, i.e. 8% and 10% respectively. The corresponding NPV (probability of recrudescence if prevalence was above the threshold) declined from nearly 60% in the
scenario with six MDA rounds with 60% coverage to about 25% in the scenario with eight
MDA rounds with 80% coverage (Fig I in S1 Supplement). The PPV of the suggested threshold
was slightly higher among runs with 30–40% baseline Mf prevalence than in runs with 20–30%
baseline Mf prevalence (Fig J in S1 Supplement).
The PPV for a given Mf or CFA prevalence threshold increases with the number of people
sampled and thresholds associated with 95% PPV shift to higher values (Fig K in S1 Supplement). Mf prevalence thresholds still remain low, and the PPV for CFA prevalence among 6-
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Fig 3. Receiver-operator characteristic (ROC) curves for predicting the eventual occurrence of elimination of transmission under different MDA
scenarios, based on the simulated microfilaraemia (Mf) or circulating filarial antigenaemia (CFA) prevalence 1 year after the last treatment round.
Different lines show the predictive performance of the Mf and CFA prevalence assessed in all people aged 5 or 15 years and above (Mf: red and grey; CFA:
green and pink) and the CFA prevalence in all 6-7-year-old children (blue). Sensitivity is the percentage of simulation runs ending in elimination that are
correctly identified based on Mf or CFA prevalence below a range of thresholds (see legend). Similarly, 100%-specificity is the percentage of simulation
runs that is falsely classified as having achieved elimination, out of all runs that did not result in elimination, resulting in premature stopping of MDA. The
optimal situation is in the upper left corner of the panels (100% sensitivity and 100% specificity). Results are based on 2000 simulations per scenario, with
baseline Mf prevalence varying between 20% and 40%.
https://doi.org/10.1371/journal.pntd.0010953.g003

7-year olds never exceeds 90%. For a given sample size, measuring CFA or Mf in the 15+ population results in slightly higher PPV and higher threshold values than measuring CFA prevalence in the 5+ population, because the prevalence of infection is lower in 5–15 year old
children. Halving or doubling Mf-productivity (while doubling or halving the biting rate) had
hardly any impact on the pre-control Mf-CFA prevalence association and the positive predictive value of the suggested thresholds (Figs L and M in S1 Supplement).
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Fig 4. Probability of achieving elimination within 50 years after the last round of MDA, if the 1-year post MDA prevalence was below a given
threshold (i.e. the positive predictive value of using this threshold). Different lines show the predictive performance of the Mf and CFA prevalence in a
sample of 200 individuals taken from the 5+ or 15+ population (MF: red and grey; CFA: green and pink) and the CFA prevalence in a sample of 200 67-year-old children (blue). Results are based on 2000 simulations per scenario, with baseline Mf prevalence varying between 20% and 40%. The PPV
curves based on CFA prevalence in the 5+ or 15+ population are somewhat erratic at low prevalences in the panel for settings that had 6 rounds of MDA
with 60% coverage. This is explained by the fact that only few simulation runs ended with such low CFA prevalences in this treatment scenario (i.e. the
denominator for calculating the PPV). If one of these few runs ended in resurgence, it causes relatively large fluctuations in the estimated PPV.
https://doi.org/10.1371/journal.pntd.0010953.g004

Discussion
We showed that the eventual occurrence of elimination cannot be predicted with sufficient
certainty from the CFA prevalence measured among 6-7-year-old children, irrespective of the
number tested, nor from the Mf prevalence measured in a sample of up to 200 individuals
from the 5+ or 15+ population. While the predictive value of an Mf-based stop-MDA threshold would improve if based on a full-population survey, thresholds remain low, requiring high
(and more costly) sampling sizes. Elimination can be predicted with much more certainty
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based on CFA prevalence in the 5+ or 15+ population, which has the added advantage of considerably higher thresholds and thereby smaller sample sizes needed. Focusing on the 15+ age
group may be preferred, as a high PPV can be achieved with higher thresholds and thus lower
sample sizes than when focussing on the entire 5+ population. It has the added advantage that
5–14 year old children don’t need to be tested, which could make the surveys more acceptable
to the community and easier to execute. A CFA prevalence of 10% in this population subgroup
corresponds to a PPV of 95% or higher, and this threshold is robust for endemicity level and
number of MDA rounds.
The proposed CFA threshold, chosen for its high PPV (�95%), is associated with a relatively low NPV (i.e. the probability of resurgence if the prevalence is above the threshold), with
NPV values between 25% and 60% depending on the treatment scenario. We consider this
acceptable as the consequence of a false negative outcome (continuing MDA for too long at
the cost of wasting drugs and other resources) is less of a problem than a false positive result
(stopping MDA too early and having to reinstate the MDA infrastructure).
To reproduce the pre- and post-MDA Mf-CFA prevalence association with our model, it
was sufficient to assume that CFA positivity occurs when an individual has at least one mature
worm, even though village-specific time trends in Mf and CFA prevalence were not always
matched exactly. Some unexplained variation remains in the data, which may be due to sampling variation or other factors not captured in the model. For example, direct comparison of
the ICT card test and the Filarial Test Strip (FTS) for measuring antigenaemia suggested that
the latter is more sensitive, especially in low endemic settings [13]. Accounting for this would
bring the model closer to the relatively low ICT-based CFA prevalences observed in Liberia
(Fig 1). Also, accounting for the impact of ivermectin MDA for onchocerciasis prior to the
trial onset in Côte d’Ivoire, could help to reproduce observations with relatively low Mf prevalence and high CFA prevalence, as ivermectin causes a strong reduction in Mf density but does
not kill adult worms [20,21]. Further refinement of the diagnostic model, e.g. to capture temporal dynamics of antigenaemia density after worm-death or a possible differential contribution of male and female worms to antigenaemia density, requires more-detailed individuallevel infection and treatment data. More detailed modelling of antigenaemia decay rates would
likely have little impact on model predicted antigenaemia prevalences 12 months after treatment, on which our threshold estimates were based. However, even If CFA tests remain positive that long after treatment-induced death of the last worm, this would not change the main
findings, but would only result in slightly higher threshold values.
Uncertainty is inherent to modelling, e.g. concerning the values of model parameters or
model structure. We used the LYMFASIM model, which was quantified for Anopheles-transmitted bancroftian filariasis in Africa and was validated in this study against data from West
Africa. It is reassuring that our PPV and NPV estimates for CFA prevalence among 6-7-year
olds are fairly similar to those estimated with another simulation model [22]. Their estimates
for Malindi (a Kenyan village with baseline endemicity within our simulated range) are comparable to our estimates from the most intensive MDA scenario (with eight MDA rounds and
80% coverage), both with respect to the overall probability of elimination and the PPV of different infection indicators. We anticipated that our predictions would be influenced by
assumptions about the ratio of Mf to adult worm density. We explored the impact of using a
different Mf productivity rate, but found that doubling or halving this value (and thus halving
and doubling corresponding worm burdens) did not change the overall conclusions regarding
the relative performance of different indicators for stopping. Still, in-depth analysis of individual-level Mf and CFA positivity or density data could help to quantify such uncertain parameters to further improve the accuracy of our model [23].
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WHO chose to assess infection in 6-7-year-old children, as any infection in this age group
must be recently acquired, meaning that transmission has not been completely interrupted [6].
Focussing on this age group is also practical, as it allows for school-based sampling. The 2%
CFA prevalence threshold was assumed to be “a conservative proxy for an Mf prevalence of
<1%”, considering the higher sensitivity of CFA tests for detecting infection [6]. However, our
study clearly demonstrates that CFA prevalence in this age group is not the most informative
predictor of the eventual achievement of elimination. As 6-7-year olds constitute a small proportion of the population and are less exposed than older individuals, even a zero prevalence
in this group does not preclude eventual resurgence of LF in the population (demonstrated by
the model-estimated PPV values in this age group never exceeding 90%).
Our simulations were specific for African areas where LF is transmitted by Anopheles-species and ivermectin plus albendazole is the MDA treatment regimen. Our thresholds are not
valid for areas, where LF is transmitted by different vector species (e.g. Culex or Aedes). Especially the Aedes-vectors are known to be highly efficient, which led WHO to propose lower
stop-MDA thresholds for areas with Aedes transmission. The employed treatment regimen
can also influence the post-MDA CFA-Mf association and hence the CFA-thresholds. However, our conclusions about the insufficient sensitivity of TAS in 6-7-year-old children are generalizable. Indeed, concerns about the reliance on measures in such young children were
voiced before, when evidence of persistent LF transmission was found after passing TAS and
stopping MDA, e.g. in Sri Lanka and American Samoa [24–27]. Detailed studies in these countries carried out several years after passing TAS and stopping MDA, confirmed that CFA prevalence in such young children was considerably lower than the prevalence among older
individuals or adults only [11,28]. Moreover, these studies demonstrated that communitybased TAS is feasible, although it is logistically more difficult, takes more time and is more
expensive.
Our quantitative CFA prevalence threshold estimates (10% in 15+) should be interpreted
with caution, also for the African context. They are based on modelling and our long-term
elimination predictions remain to be validated. These quantitative thresholds apply to communities with moderate to high baseline Mf prevalence (between 20% and 40%) and under the
specified transmission and treatment conditions. In reality there may be more variation in
transmission conditions, treatment history, or age-infection patterns, which can influence the
safe threshold values. For example, lower thresholds may be needed in settings where low preMDA Mf prevalence is stabilized by continued imported infection from surrounding areas or
strong aggregation of exposure, as was shown in other theoretical studies for filarial infections
[22,29,30]. To obtain more certainty about the stop-MDA decision, presence of Mf can be
assessed in CFA positives to ensure absence of a significant Mf reservoir for transmission. This
is feasible, as night blood sampling and processing would be required for a limited number of
people. If stop-MDA decisions are made for larger geographical areas, encompassing multiple
communities with varying baseline endemicities, thresholds should be adjusted to account for
heterogeneity within the area. This is most obvious when the area includes non-endemic communities, which cause dilution of infection levels for the endemic part of the area, requiring
lower threshold levels.
We conclude that the currently used CFA prevalence in 6–7 year-old children is a poor
indicator for stopping decisions in LF control by MDA if elimination of transmission is the
eventual goal. We recommend using CFA prevalence of the 15+ population at a threshold of
10% (with Mf follow-up) as critical threshold for stopping MDA in LF elimination programmes where treatment has been provided for at least 5 or 6 years with adequate coverage,
for application at the level of communities or somewhat larger areas with relatively homogeneous transmission conditions.
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Methodology: Wilma A. Stolk, Luc E. Coffeng, T. Déirdre Hollingsworth, Edwin Michael, Joaquin M. Prada, Rocio M. Caja Rivera, Swarnali Sharma, Panayiota Touloupou, Sake J. de
Vlas.
Project administration: Sake J. de Vlas.
Software: Wilma A. Stolk, Luc E. Coffeng.
Supervision: Peter U. Fischer, Gary J. Weil, Sake J. de Vlas.
Validation: Luc E. Coffeng.
Visualization: Wilma A. Stolk, Luc E. Coffeng, Sake J. de Vlas.
Writing – original draft: Wilma A. Stolk.
Writing – review & editing: Wilma A. Stolk, Luc E. Coffeng, Obiora A. Eneanya, Peter U.
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